Short answer
Exelixis Inc (EXEL) filed its Q4 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Oct 2, 2026. Quarterly revenue was $659M (up 10.2% year over year) with net income of $218M.
Q4 2026 key financials · XBRL
- Revenue
- $659M
- +10.2% YoY · +4.8% QoQ
- Net income
- $218M
- +12.7% YoY · +2.9% QoQ
- Operating margin
- 40.8%
- EPS (diluted)
- $0.86
- +22.9% YoY · +6.2% QoQ
Source: XBRL data from the Exelixis Inc (EXEL) Q4 2026 10-Q on SEC EDGAR. USD.
Exelixis Inc Q4 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $658.7M vs $597.8M YoY, up $60.9M
- Net income $218.1M vs $193.6M YoY, with effective tax rate 22.9% vs 23.3%
- Best product CABOMETYX revenue $603.2M vs $539.9M, up $63.3M
- Cash, equivalents and securities $1.4B vs $1.7B at December 31, 2025
- Operating cash flow $839.5M, stock repurchases $402.1M through September 30, 2026
- Outlook: revenue may increase, while reimbursement pressure, tariffs and generic competition remain headwinds
Risk Factors
- No material changes to risk factors disclosed in Fiscal 2025 Form 10-K
- Carried-forward business risk: unidentified or currently immaterial risks may impair operations
- Carried-forward financial risk: existing risks could materially adversely affect financial condition and results of operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Exelixis Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.